This paper presents a disposable minimally invasive self-calibrating continuous glucose monitor consisting of hollow out-of-plane microneedles to sample interstitial fluid from the epidermis, an integrated porous poly-Si dialysis membrane and an integrated enzyme-based flowthrough glucose sensor. The proposed system can be fabricated on a wafer-level using standard MEMS technology and a novel in-device enzyme immobilization technique that allows wafer-level patterning of enzymes inside micro-scale flow channels after wafer bonding. This technique solves the compatibility issue of high temperature wafer bonding and temperature sensitive enzymes. A prototype of the glucose monitor is fabricated in order to demonstrate the bigb potential of out-of-plane microneedles for this application. Sampling of interstitial fluid through the microneedles results in a significant sensor response of the integrated glucose sensor.
INTRODUCTION
According to the World Health Organization (WHO) the number of people affected by diabetes increased worldwide from 135 million (2.4%) in 1995 to 177 million (2.9%) in 2000 and it is expected to reach 370 million (4.5%) in 2030. This implies a tremendous growth of over 100% of the total number of diabetics within the next three decades. The number of people with diabetes in the USA is projected to increase from 18 million (6.0%) in 2000 up to 30 million (8.4%) in 2030 (Fig. I) . Diabetes is not only a handicap for the affected patients but also a considerable burden on national health systems and societies. In 1997 the total cost of treating diabetes h t h e USA was estimated at US$44 billion. Diabetes is the leading cause of blindness, kidney failure and non-traumatic amputation of the lower limb.
. Further severe complications are neuropathy and heart disease.
While frequent and long periods of hyperglycemic blood glucose levels account for these long-term complications, hypoglycemia (blood glucose level below 50mg/dl) can cause sudden coma and brain damage. Periodic fingerstick tests often fail to detect all hypoglycemic and hyperglycemic events since glucose levels can change rapidly (2.25 mg/dl/min). Especially nocturnal hypoglycemia often remains undetected (Fig. 2) . The capability to easily and continuously monitor the blood glucose level would be a tremendous improvement in the treatment of diabetes. A painless approach is to measure the glucose level of the interstitial fluid, which correlates well with the blood glucose level. However, the currently available continuous monitoring systems, the Cygnus GlucoWatch" and the Minimed CGMSTM, cannot provide accurate or everyday glucose monitoring and still require fingerstick tests for periodic sensor recalibration. The GlucoWatcha is easy to use but relies on reverse iontophoretic sampling of interstitial fluid through the skin [I]. Fluctuating skin permeability and perspiration cause inaccurate sensor readings. The MiniMed CGMSTM provides accurate sensor readings but is not designed for daily usage since trained personnel is required to insert the glucose sensor undemeath the skin [2]. The enzyme-based flaw-through glucose sensor consists of a Pt working electrode (WE), an Ag/AgCI reference electrode (RE) and a PI counter electrode (CE). The glucose oxidase (GOX) is immobilized upstream from the working electrode inside the flow channel. An integrated diffusion harrier prevents glucose diffusion from the calibration fluid into the dialysis fluid during sensor recalibration.
MICRONEEDLE-BASED CONTINUOUS GLUCOSE MONITOR
In the presence of dissolved oxygen glucose oxidase immobilized inside the channel catalyses the oxidation of glucose to gluconic acid. Hydrogen peroxide is formed as a by-product.
The hydrogen peroxide is detected downstream using an integrated electrochemical sensor [5]. The working electrode is biased 0.7 V versus the reference electrode. Thus, hydrogen peroxide is oxidized at the working electrode and the resulting electric current is proportional to the glucose concentration inside the dialysis fluid.
Since the chlorine ion concentration in biological fluids remains constant at 0.15 mM a simple planar AgiAgCl electrode can serve as a pseudo reference electrode. For automatic sensor recalibration reference glucose solution is periodically pumped past the sensor. Thus, no fingerstick tests are required to account for the usual loss of enzyme activity within the desired total sensor operation time of 72 h. The diffusion barrier consisting of a long diffusion path prevents diffusion of glucose from the calibration fluid into the dialysis fluid during sensor recalibration.
The response time of the system is mainly defined by the glucose diffusion rate into the microneedles and through the dialysis membrane. Assuming rapid glucose diffusion through the 1 O O n m thin membrane a good estimation for the response time is the time required to establish the concentration equilibrium inside the microneedles. Figure 4 .shows the theoretical sensor response to a fast decreasing glucose concentration (2.25 mgidllmin). The time lag of the sensor signal is only 2 min. Thus, save sensor operation requires an alarm level for hypoglycemia at 54.7 mg/dl. 
IN-DEVICE ENZYME IMMOBILIZATION: INTEGRATED GLUCOSE SENSOR
Wafer-level fabrication of the integrated glucose monitor requires anodic wafer bonding (7'2 350 "C), which allows easy bonding of a structured Pyrex" wafer to a structured silicon wafer. Glucose oxidase denatures at temperatures above 65 "C. Therefore a novel in-device immobilization technique has been developed, which allows wafer-level pattering of enzymes inside microscale flow channels after wafer bonding. This method uses poly(viny1 alcohol)-styrylpyridinium (PVA-SbQ)', a water-soluble photosensitive polymer, to entrap the enzymes [6] . Therefore, PVA-ShQ (SPP-H-13 Bio) is mixed 1 : 1 with phosphate buffered saline (PBS) solution (0.01 M, pH 7.4) containing 45.6 pg/ml glucose oxidase from Aspergihs mger. This enzyme-polymer mixture is filled into the flow channels and selectively polymerized under W light (365 nm, 750 mJ/cm2) through the Pyrex' cover using a shadow mask (Fig. 5) . Thus, enzymes get entrapped in the locally formed gel. No significant loss of glucose oxidase activity could be measured for the exposure energy required to polymerize the PVA-SbQ. Finally the unlinked enzyme-polymer solution is rinsed out while the active gel remains inside the flow channels (Fie. 6). Critical for wafer-level in-device immobilization is to include auxiliary channels in the wafer layout (Fig. 7) , which connect all sensor devices and a!low easy filling of the entire wafer stack and flushing of the unlinked I PVA-ShQ from Toyo Gosei, Tokyo, Japan TRANSDUCERS '03
The l a h International Confsrence on Solid State Sensors, Actuators and Microsystems. Boston. After enzyme immobilization the wafer stack is diced into chips (Fig. 8) . This opens the auxiliary channels between the sensor devices, which are now used as inplane device fluid ports. Capillaly tubes (OD = 360 pm) are glued into these fluid ports using fast curing epoxy adhesive.
One device dicing

BOnd pads
One device The chip design also allows easy-bond pad access after wafer dicing. Since the bond pads are located in a shallow trench in the Pyrex' cover the silicon overlapping the bond pads remains unbonded. First, only the silicon wafer is cut as showi in Figure 9 . The overlapping silicon breaks off readily after dicing the wafer stack (through , cuts) giving access to the bond pads. The silicon is cut first before the wafer stack is diced into chips (through cuu). Thus, the overlapping silicon breaks of readily, which gives access to the bond pads. Figure IO shows the calibration curve of the integrated flow-through glucose sensor for a flow rate of 100 pl/min. At this flow rate the glucose supply is much faster than the catalytic reaction of glucose to gluconic acid and hydrogen peroxide. Thus, the glucose level along the channel remains constant and the sensor characteristic mainly depends on the enzyme kinetics. Curve fitting of the measured data with the Michaelis-Menten equation Figure 11 shows that the optimum flow rate for the integrated flow-through glucose sensor is 25 pVmin. At lower flow rates all of the supplied glucose reacts40 gluconic acid and hydrogen peroxide. Increasing the flow rate increases the glucose supply in the channel, which increases the production rate of hydrogen peroxide. In addition the transport time of hydrogen peroxide to the sensor decreases, so that more hydrogen peroxide can 
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reach the working electrode before it dissociates to oxygen and water. For higher flow rates the glucose concentration along the channel remains constant while the hydrogen peroxide concentration in the dialysis fluid decreases due to increasing dilution. Thus, the sensor signal decreases with an increasing flow rate.
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FIRST PROTOTYPE
The first prototype (Fig. 12) Sampling interstitial fluid from the skin (finger) through the microneedles results in a 'significant sensor response. However, capillary forces are not sufficient to maintain a constant flow of interstitial fluid past the sensor so that the signal decreases after reaching its maximum (Fig: 13) . The amount of glucose simply diffusing through the eight microneedles is not sufficient for a significant sensor response. However, an array of 1000 out-of-plane microneedles (8 mm x 8 mm area) is expected to provide sufficient sensor signals. 
CONCLUSIONS
A novel in-device enzyme immobilization technique has been developed. This method is essential for waferlevel fabrication of the proposed microneedle-based glucose monitor since it allows wafer-level pattering of enzymes inside micro-scale channels after wafer bonding. Thus, it solves the compatibility issue of temperature sensitive enzymes and the required high temperature wafer bonding. An integrated enzyme-based flow-through glucose sensor has been fabricated using in-device enzyme immobilization. The sensor response is linear in a glucose concentration range of 0 -160 mg/dl. The optimum flow rate of this sensor is 25 pYmin. First measurements using a prototype of the glucose monitor consisting of out-of-plane microneedles and the integrated glucose sensor show that the used microneedles are capable to sample epidermal interstitial fluid. 
